 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BARACLUDE safely and effectively. See full prescribing information for BARACLUDE.

First Page		Document Content
Date: 2012-10-15 15:53:23 Organic chemistry Organofluorides Bristol-Myers Squibb Gilead Sciences Lamivudine Entecavir Hepatitis B Antiretroviral drug Adefovir Chemistry Purines Medicine		 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BARACLUDE safely and effectively. See full prescribing information for BARACLUDE. Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 345,71 KB Share Document on Facebook

	DEPARTMENT OF BIOCHEMISTRY FRONTIERS PROFESSOR KENNETH JOHNSON Roger J. Williams Centennial Professor of Biochemistry, University of Texas, USA DATE DocID: 1pw8Q - View Document
	Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (aoûtANRS 167 LAMIDOL Essai pilote évaluant un traitement de maintenance par lamivudine et dolutégravir chez le DocID: 1nVRg - View Document
	Microsoft WordNational Summit Evaluation DocID: 1lQ90 - View Document
	Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (aoûtANRS 167 LAMIDOL Essai pilote évaluant un traitement de maintenance par lamivudine et dolutégravir chez le DocID: 1lhUm - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULYZAQ safely and effectively. See full prescribing information for FULYZAQ. FULYZAQ ® (crofelemer) delayed-releas DocID: 1gtlL - View Document